Online citations, reference lists, and bibliographies.
← Back to Search

Cyclosporine-loaded Microspheres For Treatment Of Uveitis: In Vitro Characterization And In Vivo Pharmacokinetic Study.

Y. He, Y. Liu, Y. Liu, J. Wang, X. Zhang, W. Lu, Zhi-Zhong Ma, X. Zhu, Qiang Zhang
Published 2006 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE A sustained intraocular level of immunosuppressive drug is desirable for the treatment of uveitis and other intraocular immune disorders. The objective of the present investigation was to assess the suitability of cyclosporine-loaded poly(lactic-co-glycolic acid) microspheres (CyS-PLGA-MS) to achieve this goal. METHODS A solvent-evaporation method was used in the preparation of CyS-PLGA-MS. These microspheres were characterized for drug loading, entrapment efficiency, and in vitro release by high-performance liquid chromatography, particle size by phase-contrast light microscopy and surface morphology by scanning electron microscopy. The 3H-CyS-PLGA-MS suspension was injected into the vitreous body of healthy rabbits, and the concentration of cyclosporine in various ocular tissues and blood at predetermined intervals was measured by a scintillation counting technique and the pharmacokinetic parameters were calculated. Intravitreous administration of 3H-CyS solution was conducted as the control. RESULTS The CyS-PLGA-MS was produced, with drug-loading ranging from 11% to 16% and a high entrapment efficiency from 86% to 98%. Microspheres were discrete, spherical particles with a diameter of approximately 50 microm. The CyS was constantly and slowly released from microspheres in the in vitro release experiment. Compared with CyS solution, microspheres prolonged the release of CyS and maintained therapeutic CyS concentrations for at least 65 days in disease-related tissues such as the choroid-retina and iris-ciliary body. The percentage of CyS released in vitro correlated well with the CyS distribution rate in vivo. CONCLUSIONS CyS-PLGA-MS, displaying sustained intraocular release of CyS and showing advantages over CyS solution, may meet clinical needs more efficiently.
This paper references
Preparation, characterization and in vitro release kinetics of aminophylline loaded albumin microspheres
J. Singh (1994)
10.1016/S0165-2427(00)00219-1
Effect of an intravitreal cyclosporine implant on experimental uveitis in horses.
B. Gilger (2000)
10.1007/s004170050321
Efficacy of subconjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit
Maria Victoria de Rojas Silva (1999)
10.1373/clinchem.2008.108613
Liquid-chromatographic determination of cyclosporin A in blood and plasma.
R. Sawchuk (2008)
10.2460/AJVR.2001.62.1892
Use of an intravitreal sustained-release cyclosporine delivery device for treatment of equine recurrent uveitis.
B. Gilger (2001)
10.1001/ARCHOPHT.1996.01100130307014
Evaluation of a delivery system providing long-term release of cyclosporine.
P. A. Pearson (1996)
10.1076/ceyr.24.1.39.5427
Efficacy and safety of microspheres of cyclosporin A, a new systemic formulation, to prevent corneal graft rejection in rats
Ana I Vallelado (2002)
10.1001/ARCHOPHT.1985.01050100135035
Local cyclosporine therapy for experimental autoimmune uveitis in rats.
R. Nussenblatt (1985)
10.1016/S0161-6420(98)91176-9
Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis.
G. Jaffe (1998)
10.1046/J.1463-5224.2000.00117.X
Long-term effect on the equine eye of an intravitreal device used for sustained release of cyclosporine A.
B. Gilger (2000)
10.1016/S0168-3659(02)00239-0
Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer.
W. Lee (2002)
10.1167/IOVS.02-1112
Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes.
J. Theng (2003)
10.1007/BF00915740
Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbits
C. A. Harper (2004)
10.1016/0169-409X(95)00017-2
Microspheres and nanoparticles used in ocular delivery systems
A. Zimmer (1995)
10.1016/S0168-3659(98)00146-1
Modification of release rates of cyclosporin A from polyl(L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres.
T. Urata (1999)
10.1016/S0939-6411(03)00138-3
Cyclosporine A delivery to the eye: a pharmaceutical challenge.
F. Lallemand (2003)
10.3109/02652049009028424
Controlled release captopril microcapsules: effect of ethyl cellulose viscosity grade on the in vitro dissolution from microcapsules and tableted microcapsules.
J. Singh (1990)
10.3109/03639049409038377
Preparation, Characterization and In-Vitro Release Kinetics of Salbutamol Sulphate Loaded Albumin Microspheres
S. Karunakar (1994)
Etoposide microspheres for targeting to the lung
M Schaefer (1998)



This paper is referenced by
Intravitreal delivery of corticosteroid nanoparticles
K. Mudunuri (2008)
Controlled release microparticles : impact of swelling on the drug release kinetics
H. Gasmi (2015)
10.1007/978-1-4419-9920-7_10
Microparticles as Drug Delivery Systems for the Back of the Eye
R. Herrero-Vanrell (2011)
10.1586/eop.09.70
Drug delivery to the posterior segment of the eye for pharmacologic therapy
Shalin S Shah (2010)
10.1016/j.tvjl.2015.06.017
Equine recurrent uveitis: Human and equine perspectives.
F. Malalana (2015)
10.1016/j.preteyeres.2014.04.002
The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies
R. Herrero-Vanrell (2014)
10.1097/IIO.0000000000000193
Microparticle Drug Delivery in Ophthalmology.
Benjamin G. Jastrzembski (2017)
10.1002/adhm.201700733
Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation
Michelle L. Ratay (2017)
CONTROLLED RELEASE FORMULATIONS FOR IMMUNO-REGULATION: TOWARDS A SYNTHETIC TOLEROGENIC DENDRITIC CELL
S. Jhunjhunwala (2011)
10.1016/S1773-2247(13)50016-5
Nano and microtechnologies for ophthalmic administration, an overview
R. Herrero-Vanrell (2013)
Sterol-based Organogel Drug Delivery Systems
Oliver Chung (2013)
10.1016/j.jconrel.2018.06.031
Polymer‐based carriers for ophthalmic drug delivery
Julieta C. Imperiale (2018)
Minimally Invasive Biomaterials for Central Nervous System Therapies
Britta M Rauck (2014)
10.1517/13543784.2016.1128893
Moving forward in uveitis therapy: preclinical to phase II clinical trial drug development
Raquel Salazar-Méndez (2016)
10.1155/2014/683153
Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: In Vitro Characterization Studies
Vijay D. Wagh (2014)
10.1186/1471-2415-13-39
Local therapies for inflammatory eye disease in translation: past, present and future
S. Tempest-Roe (2013)
10.1007/s13346-016-0336-5
Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases
I. Bravo-Osuna (2016)
10.3727/096368915X686779
3D-Printed Drug/Cell Carrier Enabling Effective Release of Cyclosporin a for Xenogeneic Cell-Based Therapy
Tae-Ha Song (2015)
Microparticules à libération controlée : impact du gonflement sur la cinétique de libération de substance active
H. Gasmi (2015)
10.1002/9781119041412.CH15
Polymer‐Based Augmentation of Immunosuppressive Formulations: Application of Polymer Technology in Transplant Medicine
I. Doyle (2015)
10.1201/B12950-12
Drug Delivery to the Vitreous Humor
F. Béhar-Cohen (2012)
10.1016/B978-2-294-71107-7.50055-X
Chapitre 54 – Thérapeutiques oculaires ciblées
Francine Béhar-Cohen (2010)
10.1155/2012/126463
Intravitreal Devices for the Treatment of Vitreous Inflammation
J. Christoforidis (2012)
10.1016/j.exer.2008.04.002
Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea.
I. Yenice (2008)
Cyclosporin A und dessen möglicher Einsatz
H. Gerhards (2014)
10.1016/j.drudis.2016.04.002
Modern approaches to the ocular delivery of cyclosporine A.
P. Agarwal (2016)
10.1155/2013/780634
Drug Delivery Implants in the Treatment of Vitreous Inflammation
J. Wang (2013)
10.1016/j.ejps.2018.05.015
Ocular irritation and cyclosporine A distribution in the eye tissues after administration of Solid Lipid Microparticles in the rabbit model
E. Wolska (2018)
10.7282/T33778W2
THE UTILITY OF L-TYROSINE BASED POLYCARBONATE COPOLYMERS CONTAINING POLY(ETHYLENE GLYCOL) AS A DEGRADABLE CARRIER FOR THE RELEASE OF A HYDROPHOBIC PEPTIDE MOLECULE
Isaac John Khan (2009)
10.1167/iovs.12-11466
Optimization of subconjunctival biodegradable microfilms for sustained drug delivery to the anterior segment in a small animal model.
Y. Liu (2013)
10.1016/j.ijpharm.2012.11.009
Technology of stable, prolonged-release eye-drops containing Cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM).
E. Wolska (2013)
10.3109/02713680903261405
Cyclosporine A-Loaded Solid Lipid Nanoparticles: Ocular Tolerance and In Vivo Drug Release in Rabbit Eyes
E. Gökçe (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar